Search results

Found 49 pages
AUTHOR: Claire Bowie

Results per page

10 20 50 100

Sort by

Relevance Date

17 Nov 2014:

Pharma should be involved in fight against obesity

Having successfully led the bid for London to host the 2012 Olympic Games, Lord Sebastian Coe – winner of four Olympic gold medals turned MP, life peer and now champion of the nation’s health – has a new mission to get us a

by Claire Bowie

https://www.pharmatimes.com/news/pharma_should_be_involved_in_fight_against_obesity_1002773

12 Aug 2009:

AstraZeneca and Forest hook up for antibiotic

AstraZeneca and Forest Laboratories have hooked up to develop and market a new antibiotic – ceftaroline – in all markets outside of the USA, Canada and Japan. The deal for Forest’s late-stage cephalosporin “complements our existing

by Claire Bowie

https://www.pharmatimes.com/news/astrazeneca_and_forest_hook_up_for_antibiotic_983840

13 Aug 2009:

Lundbeck sees 2Q revenue jump 18%

Denmark’s Lundbeck A/S has bucked the recession and posted second quarter revenue up 18% at constant exchange rates to 3.4 billion kroner as key drugs Cipralex (escitalopram; up 12% to 1.3 billion), Ebixa (memantine; up 18% to 539 million) and

by Claire Bowie

https://www.pharmatimes.com/news/lundbeck_sees_2q_revenue_jump_18_983830

7 Oct 2010:

Gene raises MI risk 29%, international consortia finds

An international consortium of researchers have identified multiple genetic mutations for heart attack and coronary heart disease, including one gene that increases heart attack risk by 29%. - News - PharmaTimes

by Claire Bowie

https://www.pharmatimes.com/news/gene_raises_mi_risk_29,_international_consortia_finds_982291

30 Jun 2009:

Novartis to purchase Ireland’s Elan? Tysabri update

Could Swiss giant Novartis soon be the proud new owner of much of Ireland’s Elan? It could be just another rumour but the UK’s Sunday Times cites a “well placed source” as saying parts of Elan, including its multiple sclerosis products and

by Claire Bowie

https://www.pharmatimes.com/news/novartis_to_purchase_irelands_elan_tysabri_update_984575

19 Jun 2009:

Biologics set to dominate pharma sales

Seven of the top 10 and all of the top six drugs will be biologics in just five years time, says a new report from analysts at Evaluate Pharma. Heading the pack will be Roche’s cancer antibody Avastin (bevacizumab) – reeling in $9.2 billion in

by Claire Bowie

https://www.pharmatimes.com/news/biologics_set_to_dominate_pharma_sales_984650

26 Mar 2007:

Merck sees European nod for Januvia

Merck & Co was celebrating yesterday after winning approval in Europe to market the potential star in its pipeline – the once-daily diabetes treatment Januvia (sitagliptin). The compound becomes the first in the class of so-called dipeptidyl

by Claire Bowie

https://www.pharmatimes.com/news/merck_sees_european_nod_for_januvia_989598

23 Jan 2008:

BMS takes Exelixis’ hedgehog drug under its wing

Bristol-Myers Squibb yesterday revealed it has exercised a pre-existing option and will take Exelixis’ XL139 into the fold. The compound is a small molecule inhibitor of the so-called hedgehog pathway, which is thought to play a critical role in a

by Claire Bowie

https://www.pharmatimes.com/news/bms_takes_exelixis_hedgehog_drug_under_its_wing_985925

21 Jan 2008:

No silver bullet for obesity

While the obesity epidemic is indisputable – as is the consequential health burden on society – the growth in use of antiobesity agents is failing to mirror the burgeoning patient population because of a lack of reimbursement by governments,

by Claire Bowie

https://www.pharmatimes.com/news/no_silver_bullet_for_obesity_985948

8 Oct 2009:

AZ's Seroquel in the dock over "weight neutral" claims

AstraZeneca’s multibillion-dollar drug Seroquel (quetiapine) was in the spotlight again this week after internal documents showcased at a pre-trial examination of John Patterson, now-retired executive director of product development, suggested the

by Claire Bowie

https://www.pharmatimes.com/news/azs_seroquel_in_the_dock_over_weight_neutral_claims_984489